Pressure on Europe’s drug agencies can be eased through public and private means
This article was originally published in Clinica
The global economic crisis has placed many European industries under financial pressure. To date, however, the pharmaceutical industry has appeared to be remarkably resilient for one simple reason: society demands health. Yet, whilst the industry has maintained a sense of imperviousness, some of the EU member state medicines agencies – many responsible for regulating both pharmaceuticals and medical devices – are beginning to buckle under the pressure of the economic downturn, coupled with the increasing legislative demands that emanate from Brussels.